The use of PD-1/PD-L1 inhibitors is theoretically more appropriate for patients with HIV-associated cancers, but in practice the unknown adverse effects that may be caused by the immunocompromised state of HIV patients have limited their use in this population. Here, PDCD1 is linked to cancer.